Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167233 | 0.90 | ALDH1A1 (0.47) | MAPTGAAEPHB4POLBLMNA | |
| SCHEMBL165141 | 0.88 | ALDH1A1 (0.42) | MAPTGAAEPHB4POLBLMNA | |
| SCHEMBL15077845 | 0.84 | CCR2 (0.43) | MAPTGAATP53TRPV1EPHB4 | |
| SCHEMBL166071 | 0.81 | ALDH1A1 (0.42) | MAPTGAATP53EPHB4POLB | |
| SCHEMBL15077847 | 0.78 | TRPV1 (0.46) | MAPTGAATP53TRPV1EPHB4 | |
| SCHEMBL15077850 | 0.75 | CCR2 (0.41) | MAPTEPHB4POLBLMNAMEN1 | |
| SCHEMBL9989438 | 0.74 | MAPT (0.44) | MAPTTP53EPHB4POLBLMNA | |
| SCHEMBL15054097 | 0.72 | BRAF (0.38) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15053595 | 0.71 | BRAF (0.37) | MEN1KMT2A | |
| SCHEMBL15052734 | 0.71 | ALDH1A1 (0.44) | MAPTEPHB4POLBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | MAPT 1276/4885GAA 2720/4885TP53 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.